CLINICAL AND HEMODYNAMIC EFFICACY OF CHOLINE ALFOSCERATE IN ARTERIAL HYPERTENSION AND HYPERTENSIVE ENCEPHALOPATHY
Keywords:
arterial hypertension, blood pressure, cognitive disorders, hypertensive encephalopathy, cerebral blood flow disordersAbstract
Arterial hypertension (AH) is currently considered the most significant risk factor for the development of not only acute cerebrovascular accidents and chronic cerebral ischemia, but also disorders of memory and other cognitive (cognitive) functions. Numerous studies have proven the connection between persistent increase in blood pressure (BP) and the risk of the onset and progression of cognitive impairment. The positive dynamics on the part of clinical and hemodynamic parameters is explained by the fact that gliatilin improves the transmission of nerve impulses in cholinergic neurons; positively affects the plasticity of neuronal membranes and receptor function. Gliatilin improves cerebral blood flow, enhances metabolic processes in the brain, activates the structures of the reticular formation of the brain and restores consciousness in traumatic brain lesions. The data obtained by us require further, more in-depth study, however, at this stage, it seems appropriate to include gliatilin in the complex treatment of patients with AH and hypertonic ensefalopaty.
References
Zakharov V.V., Yakhno N.N. Cognitive disorders in old and senile age: Method, manual for doctors. M., 2005.
Rumyantseva G.M. et al. // Qualitative clinical practice. 2002. No. 1. P. 28.
Sevastyanova E.V., Poverennova I.E. // Nevrol. vestn. 2008. T. XL. Issue 1, p. 21.
Cerebrovascular Disease, Cognitive Impairment and Dementia / Ed. by J. O'Brien et al. L., 2004.
Cicconetti P. et al. // Clin. Exp. Hypertens. 2000. V. 22. P. 583.
Cherubini A. et al. // Am. J. Ther. 2007. V. 14. P. 533.
Di Bari M. et al. // Am. J. Epidemiol. 2001. V. 153. P. 72.
Forette F. et al. // Arch. Intern. Med. 2002. V. 162. P. 2046.
Morris J. et al. // Arch. Neurol. 2001. V. 58. P. 397.
McGuinness B. et al. // Cochrane Database Syst. Rev. 2006. V. 2.CD004034.
Muller W.E. et al. // Pharmacopsychiatry. 1999. V. 32. Suppl. 1.P.2.
